Mogal Harveshp D, Levine Edward A, Russell Greg, Shen Perry, Stewart John H, Votanopoulos Konstantinos I
Division of Surgical Oncology, Department of General Surgery, Wake Forest Baptist Health, Winston-Salem, NC, USA.
Department of Biostatistics, Wake Forest Baptist Health, Winston-Salem, NC, USA.
Ann Surg Oncol. 2016 Feb;23(2):534-8. doi: 10.1245/s10434-015-4821-8. Epub 2015 Aug 20.
Survival of patients after cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy for appendiceal neoplasms is projected by conventional overall survival (OS) curves that do not address the survival time a patient has already accrued. We sought to study the conditional survival (CS) after CRS, contingent on patients surviving a fixed duration of time after surgery.
A retrospective analysis of 493 appendiceal cancer patients from a prospective database was performed. OS was calculated for patients who achieved a complete CRS. CS was estimated based on Kaplan-Meier curves to determine what the patient's long-term survival (3-, 5-, 7-, or 10-year) would be if they were alive at 1, 2, or 3 years from surgery.
OS at 5 and 10 years for 137 low-grade patients with complete resections was 83.3 and 74.2 %, respectively. For low-grade patients still alive at 3 years, 5- and 10-year CS was 93.4 and 83.2 %, respectively. For the 35 high-grade patients with complete CRS who survived to 3 years, CS at 10 years was 41.7 %, while their 10-year conventional OS was 24.6 %.
Conventional analysis underestimates OS due to unpredictable variations in tumor biology. When adjusted for time already elapsed since surgery, improvements in survival estimates are more pronounced with high-grade tumors. CS outcomes can be used in determining the optimal frequency of long-term follow-up of these patients.
对于阑尾肿瘤患者,细胞减灭术(CRS)及术中温热腹腔化疗后的生存率是通过传统的总生存(OS)曲线来预测的,而这些曲线并未考虑患者已经积累的生存时间。我们试图研究CRS后的条件生存(CS)情况,即取决于患者在手术后存活固定时长后的生存情况。
对来自前瞻性数据库的493例阑尾癌患者进行回顾性分析。计算实现完全CRS的患者的OS。基于Kaplan-Meier曲线估计CS,以确定患者如果在术后1、2或3年仍存活,其长期生存(3年、5年、7年或10年)情况会如何。
137例完全切除的低级别患者5年和10年的OS分别为83.3%和74.2%。对于术后3年仍存活的低级别患者,5年和10年的CS分别为93.4%和83.2%。对于35例实现完全CRS且存活至3年的高级别患者,10年的CS为41.7%,而其10年的传统OS为24.6%。
由于肿瘤生物学存在不可预测的变异,传统分析会低估OS。当对手术后已过去的时间进行调整后,高级别肿瘤患者生存估计的改善更为显著。CS结果可用于确定这些患者长期随访的最佳频率。